Generic Drug

Type: Keyphrase
Name: Generic Drug
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

US regulator stifles Indian drug exports

India's drug export growth in 2013-14 may have dipped sharply from the projected 16-17 per cent to six-seven per cent, officials said.Pharmaceuticals - India's third fastest growing export industry - sold overseas grew 10.55 per cent to $14.65 billion ... [Published Business Standard India - Apr 19 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Court won’t block Teva rivals

Chief Justice John G. Roberts, Jr., refused on Friday afternoon to delay generic drug manufacturers from offering, as early as next month, competing and lower-priced versions of a widely used drug for treating multiple sclerosis.  In a one-page ruling, ... [Published SCOTUSblog - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Sun Pharma continues to outglow its peers

Performance is built into the DNA of Sun Pharma. The company has consistently outperformed peers and the market and 2013-14 was no exception. Last year, the company added Rs 35,000 crore, or 44 per cent, to the wealth of its shareholders.In the first ... [Published Business Standard India - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Generic Drug Delays Push Novartis's Diovan Prices Higher

A patent law quirk has allowed Novartis to exclusively market the heart drug Diovan even though its patent expired in September 2012, Bloomberg Businessweek reported Thursday. Ranbaxy holds first-to-file rights for generic Diovan, but FDA sanctions have ... [Published FirstWord Pharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Enhanced generic drug biotech Mapi-Pharma sets terms for $40 million IPO

Mapi-Pharma, which is developing enhanced generic versions of marketed drugs such as Teva's Copaxone, announced terms for its IPO on Thursday. The Ness Ziona, Israel-based company plans to raise $40 million by offering 2.9 million shares at a price range ... [Published Nasdaq - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Using a Drug-Safety Tool to Prevent Competition

In 2007, the Food and Drug Administration Amendments Act (FDAAA) created an important new tool for dealing with drugs that have potential safety problems: the Risk Evaluation and Mitigation Strategy (REMS). The aim was to encourage prescribers and patients ... [Published New England Journal of Medicine - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

What you may not know about generic drugs

An easy step by the FDA could make taking generic drugs safer. As of now, you might not know all the generic's side effects. According to Allison Zieve, director of litigation for the watchdog group Public Citizen, that's because of old FDA rules and ... [Published Hola Arkansas - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Government Causes Generic Drug Shortage, Critics Say

A proposed Food and Drug Administration rule on product labeling will exacerbate shortages of generic drugs already resulting from regulations on Medicare reimbursement rates and other factors, critics charge. ... [Published NewsMax.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Pharmaceutical Groups Seek Delay of New Generic Drug Payment Rate

In a letter sent last week to HHS Secretary Kathleen Sebelius, a coalition of drugmakers and pharmacists requested that CMS implement a one-year transition period before states implement a new provision under the Affordable Care Act that would significantly ... [Published California Healthline - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

US, EU generic drug makers call for regulatory cooperation

Generic pharmaceuticals manufacturers from Europe and the United States have urged regulators on both sides of the Atlantic to adopt a strategy of "regulatory convergence." The U.S. Generic Pharmaceutical Association (GPhA) and European Generic medicines ... [Published Processing Magazine - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 16 2014 - 3 reports

Report: Prescription Drug Spending Climbs in 2013

Total U.S.  prescription  drug spending climbed more than 3% last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health.Prescription  spending reached $329.2 ... [Published Motley Fool Discussion Boards - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Generics file response to Teva in Copaxone patent fight | Reuters

5:54pm EDT WASHINGTON (Reuters) - Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries ... [Published DailyMe.Com - Apr 15 2014]

Quotes

"Market is no mood to react on data. It's more a question of liquidity. Election results might swing the mood for a bit but liquidity would be key to watch for long term" said Phani Sekhar, fund manager at Angel Broking
"For many years, generics went down and down," said Joe Harmison, owner of DFW Prescriptions in Grand Prairie. "Within the last six to 12 months, they've been going up, some really drastically" said Harmison, who said he has operated his pharmacy for 30 years
"We have not yet arrived at the actual export calculations for 2013-14, but growth is likely to be much lower than expected. While currency fluctuation has had its adverse effect, the major contributor is regulatory actions faced by major companies" PV Appaji, director-general, Pharmaceuticals Export Promotion Council of India (Pharmexcil) told Business Standard
"Both compulsory licence for Nexavar and SC's verdict on Glivec were major blows for American companies as these moves impacted not only their Indian market but sales globally. Besides, now they run a risk of other government evaluating similar strategies" a healthcare expert said

More Content

All (913) | News (796) | Reports (0) | Blogs (103) | Audio/Video (1) | Fact Sheets (3) | Press Releases (5)
sort by: Date | Relevance
HEAT rises on health care fraud [Published Tennessean - 1 hour ago]
Do free samples influence the way doctors presc... [Published PBS - 9 hours ago]
Earnings Roundup: Look Beyond Abbott Labs' Shor... [Published Motley Fool - 14 hours ago]
Rupee ends at 1-week high, Sensex ends marginal... [Published Space View Times - Apr 20 2014]
Some generic drugs have had eye-popping price s... [Published BusinessWeek - Apr 20 2014]
What’s keeping the generic version of biologic ... [Published PBS - Apr 19 2014]
Patent rights meet on US concerns [Published Business Standard India - Apr 19 2014]
US regulator stifles Indian drug exports [Published Business Standard India - Apr 19 2014]
Cabinet Secretary set to meet top officials ove... [Published Business Standard India - Apr 19 2014]
CEO relearns, rebuilds after brain injury [Published GlobeAdvisor - Apr 19 2014]
ASK DRS. OZ & ROIZEN: Checking out generic drugs [Published Idaho Statesman - Apr 19 2014]
Court won’t block Teva rivals [Published SCOTUSblog - Apr 18 2014]
Sun Pharma continues to outglow its peers [Published Business Standard India - Apr 18 2014]
Preparing for New Generic Launches [Published PPP Mag.com - Apr 18 2014]
Investigation Report on China Esomeprazole Mark... [Published Digital Journal - Apr 18 2014]
Generic’s Counterclaims for Non-Infringement ar... [Published JD Supra - Apr 18 2014]
Sun rises on Ranbaxy [Published India Today - Apr 18 2014]
Cabinet secy calls meet on India-US pharma issue [Published Financial Chronicle - Apr 18 2014]
Fed’s Inflation Medicine Undone by Slowing Heal... [Published GARP - Apr 18 2014]
Governor for providing Red Cross Internship to ... [Published Daily Excelsior.com - Apr 18 2014]
Generic Drug Delays Push Novartis's Diovan Pric... [Published FirstWord Pharma - Apr 17 2014]
Enhanced generic drug biotech Mapi-Pharma sets ... [Published Nasdaq - Apr 17 2014]
Prosonix reaches licensing agreement with Mylan... [Published Business First of Buffalo - Apr 17 2014]
Celebrex Patent Lawsuit Settled; Teva Pharmaceu... [Published Value Walk - Apr 17 2014]
Walmart helps customer send savings [Published Retailing Today - Apr 17 2014]
Teva Pharma Reaches Settlement with Pfizer over... [Published Lawyer Herald - Apr 17 2014]
Battle of the drugstore chains: 3 stocks to watch [Published MSN Money - Apr 17 2014]
UPDATE 2-Teva settles patent suit with Pfizer o... [Published Reuters - Apr 17 2014]
Teva Settles Patent Litigation with Pfizer on C... [Published Insurance Broadcasting - Apr 17 2014]
Using a Drug-Safety Tool to Prevent Competition [Published New England Journal of Medicine - Apr 17 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Court won’t block Teva rivals [Published SCOTUSblog - Apr 18 2014]
Chief Justice John G. Roberts, Jr., refused on Friday afternoon to delay generic drug manufacturers from offering, as early as next month, competing and lower-priced versions of a widely used drug for treating multiple sclerosis.  In a one-page ruling, ...
Generic Drugmakers Fight Teva’s Bid to Stall Co... [Published Wall St. Cheat Sheet - Apr 17 2014]
Generic drugmakers asked the U.S. Supreme Court to allow them to introduce generic versions of   Teva Pharmaceutical Industries Ltd.’s ( NYSE:TEVA ) Copaxone multiple-sclerosis drug onto the market next month, according to Reuters and Bloomberg ...
The Switchboard: Al Franken seeks Netflix’s aid... [Published Faster Forward - Apr 17 2014]
Sen. Al Franken, D-Minn., confers with an aide as the Senate Judiciary subcommittee on Antitrust, Competition Policy and Consumer Rights holds a hearing on "pay-for-delay" deals between pharmaceutical companies and their generic drug competitors, which ...
The Switchboard: Al Franken seeks Netflix’s aid... [Published Post Tech - Apr 17 2014]
Sen. Al Franken, D-Minn., confers with an aide as the Senate Judiciary subcommittee on Antitrust, Competition Policy and Consumer Rights holds a hearing on "pay-for-delay" deals between pharmaceutical companies and their generic drug competitors, which ...
Bruce Braley Has History of Advocating for Tria... [Published Washington Free Beacon - Apr 15 2014]
Iowa Democrat Bruce Braley, a Senate candidate who recently criticized a fellow senator for lacking a law degree, has a long history of advocating the interests of trial lawyers, according to a Washington Free Beacon analysis. Braley is a four-time ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
CVS finds right prescription for profits [Published Reuters Video: Business - Feb 11 2014]
1

Press Releases

sort by: Date | Relevance
NEW ECONOMIC ANALYSIS SHOWS THAT FDA PROPOSED G... [Published Financial Services - Feb 05 2014]
ANI Pharmaceuticals Acquires 31 Generic Drug Pr... [Published Financial Services - Dec 26 2013]
CVS Caremark And Cardinal Health Announce Creat... [Published Financial Services - Dec 10 2013]
CVS Caremark And Cardinal Health Announce Creat... [Published Financial Services - Dec 10 2013]
Genovate and ScinoPharm Co-Develop Hepatitis B ... [Published Financial Services - Nov 11 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.